Other grade 1 or 2 toxicities such as lymphopenia and thrombocytopenia are also commonly observed when anti-IGF1R antibodies are used and are increased when anti-IGF1R antibodies are used in combination with mTOR inhibitors. The gene discussed is IGF1R; the disease is lymphopenia.